Combined Injectable Treatment for HIV and OUD

Description

This is a one-year study that seeks to evaluate perspectives of combined injectable treatment for HIV and OUD. Specifically, with the development of new long-acting medications such as cabotegravir co-administered with rilpivirine (CAB/RPV) and extended-release buprenorphine (XR-B) there is a need to better understand factors that influence the delivery and uptake of this type of treatment. Therefore, this study will conduct qualitative (1:1) interviews with 32-45 key stakeholders to assess interest, knowledge, attitudes, barriers, and facilitators to integrated injectable treatment. Our team will utilize qualitative findings to inform clinical strategies to promote uptake and maintenance of long-acting injectable medications for HIV and OUD.

Conditions

Human Immunodeficiency Virus, Opioid Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a one-year study that seeks to evaluate perspectives of combined injectable treatment for HIV and OUD. Specifically, with the development of new long-acting medications such as cabotegravir co-administered with rilpivirine (CAB/RPV) and extended-release buprenorphine (XR-B) there is a need to better understand factors that influence the delivery and uptake of this type of treatment. Therefore, this study will conduct qualitative (1:1) interviews with 32-45 key stakeholders to assess interest, knowledge, attitudes, barriers, and facilitators to integrated injectable treatment. Our team will utilize qualitative findings to inform clinical strategies to promote uptake and maintenance of long-acting injectable medications for HIV and OUD.

Integrating Long-Acting Injectable Treatment to Improve Medication Adherence Among Persons Living With HIV and Opioid Use Disorder

Combined Injectable Treatment for HIV and OUD

Condition
Human Immunodeficiency Virus
Intervention / Treatment

-

Contacts and Locations

Providence

Rhode Island Hospital, Providence, Rhode Island, United States, 02903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18-65 years of age
  • * HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay
  • * Current diagnosis of OUD according to DSM-5
  • * Able to understand and speak English and to provide written and verbal informed consent
  • * Participants recruited through RIDOC will have an additional requirement of anticipated release from jail/prison within 6 months.
  • * Currently pregnant, breastfeeding, planning to become pregnant or breastfeed during the study period
  • * Coinfection of Hepatitis B or plans to get treated for Hepatitis C during the study period

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Rhode Island Hospital,

Kirsten K Langdon, Ph.D., PRINCIPAL_INVESTIGATOR, Rhode Island Hospital

Study Record Dates

2024-10